JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on November 5, 2008; DOI: 10.1124/jpet.108.142992

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Simard, E.
Right arrow Articles by D'Orleans-Juste, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simard, E.
Right arrow Articles by D'Orleans-Juste, P.


Received for publication July 9, 2008.
Revised November 3, 2008.
Accepted for publication November 4, 2008.

CHYMASE-DEPENDENT CONVERSION OF BIG ENDOTHELIN-1 IN THE MOUSE IN VIVO

Elie Simard 1, Denan Jin 2, Shinji Takai 2, Mizuo Miyazaki 2, Isabelle Brochu 1, Pedro D'Orleans-Juste 1*

1 University of Sherbrooke 2 Osaka Medical College

* Address correspondence to: E-mail: labpdj{at}usherbrooke.ca

Abstract

The aim of this study was to identify the role of chymase in the conversion of exogenously administered big endothelin-1 in the mouse in vivo. Real time PCR analysis detected mRNA of mucosal mast cell chymase 4 and 5 as well as endothelin converting enzyme 1a and neutral endopeptidase 24.11 in pulmonary, cardiac and aorta homogenates derived from C57BL/6J mice with the later tissue expressing the highest levels of both chymase isoforms. Furthermore, hydrolysis of a fluorogenic peptide substrate, Suc-Leu-Leu-Val-Tyr-MCA, was sensitive to the chymase inhibitors Suc-Val-Pro-PheP (OPh)2 (200 µM) and chymostatin (100 µM) in supernatants extracted from the same tissue homogenates. In anesthetized mice, big endothelin-1, endothelin-1 (1-31) and endothelin-1 triggered pressor responses (ED50s; 0.67, 0.89 and 0.16 nmol/kg) which were all reduced or potentiated by selective ETA or ETB receptor antagonists, respectively (BQ-123 or BQ-788; each at 1 mg/kg). The pressor responses to big endothelin-1 were significantly reduced by the neutral endopeptidase inhibitor thiorphan (1 mg/kg) or the endothelin converting enzyme inhibitor CGS 35066 (0.1 mg/kg). In contrast, the responses to endothelin-1 (1-31) were abolished by thiorphan, but unaffected by CGS 35066. In addition, Suc-Val-Pro-PheP (OPh)2 (20-40 mg/kg) reduced by more than 60% the hemodynamic response to big endothelin-1 but not to endothelin-1 (1-31) and endothelin-1. Finally intravenous administration of big endothelin-1 induced Suc-Val-Pro-PheP (OPh)2-sensitive increases in plasma immunoreactive levels of endothelin-1 (1-31) and endothelin-1. The present study suggests that chymase plays a pivotal role in the conversion and cardiovascular properties of big endothelin-1 in vivo.


Key words: Chymase, Endothelin-1 (1-31), Mouse, Real Time PCR, Suc-Val-Pro-PheP (OPh)2, blood pressure





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.